J Korean Neuropsychiatr Assoc.  2010 Jan;49(1):20-25.

Pharmacological Treatment for Delirium in Cancer Patients

Affiliations
  • 1Department of Psychiatry, Incheon Medical Center, Incheon, Korea. minddoctor@naver.com
  • 2Department of Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • 3Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea.

Abstract


OBJECTIVES
Despite the fact that delirium is a frequent neuropsychiatric disorder in cancer patients, there are, in Korea, no guidelines for the pharmacological treatment of such delirium. This systematic review evaluated the efficacy and safety of some pharmacological interventions and summarized the results.
METHODS
We searched PubMed, Embase, CINAHL, the Cochrane Library, and the KMbase, targeting from January 1990 to October 2008, using key words. Moreover, we included systematic reviews, meta-analyses, and randomized controlled trial literature in the search. Then, we stratified the trials based on their evidence levels.
RESULTS
AND CONCLUSION: We identified 13 randomized, controlled studies and 2 case-control studies that met our inclusion criteria. These showed that haloperidol was the medication of choice to treat delirium. In addition, they revealed that atypical antipsychotics have not shown clear superiority with regard to effectiveness as compared to haloperidol. Neither donepezil nor rivastigmine were shown to be effective in preventing or treating delirium.

Keyword

Delirium; Cancer; Pharmacological treatment

MeSH Terms

Antipsychotic Agents
Case-Control Studies
Delirium
Haloperidol
Humans
Indans
Korea
Phenylcarbamates
Piperidines
Rivastigmine
Antipsychotic Agents
Haloperidol
Indans
Phenylcarbamates
Piperidines
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr